Transcutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk

Carotid Stenosis Clinical Trial

Official title:

Transcutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04063709
• Other study ID #: 17-2700
• Secondary ID: R01HL092944-06A1
• Status: Recruiting
• Phase: N/A
• Start date: July 17, 2019
• Est. completion date: July 16, 2024

Study information

• Verified date: May 2023
• Source: University of North Carolina, Chapel Hill
• Contact: Melrose Fisher, RN
• Phone: 919-819-9054
• Email: mwfisher54[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Stroke is a leading cause of death and disability in the United States and around the world. The goal of this work is to develop and test a noninvasive ultrasound-based imaging technology to better identify patients at high risk of stroke so that appropriate and timely intervention may be administered to prevent it.

Description:

Although stroke remains a leading cause of death in the United States, incidence and mortality rates have declined over the past two decades in association with advanced pharmaceutical therapies and revascularization, primarily by carotid endarterectomy (CEA). While CEA's efficacy for preventing stroke in patients with severe (≥70%) carotid artery stenosis and neurological symptoms is well documented, the surgical intervention's usefulness decreases as stroke risk falls in patients with less severe stenosis and patients without symptoms. It is estimated that as many as 13 out of 14 symptomatic patients with 50-69% stenosis and 21 out of 22 asymptomatic patients with 70-99% stenosis undergo CEA surgery unnecessarily. These data demonstrate the inadequacy of degree of stenosis as the primary indication of stroke risk and underscore the urgent yet unmet need for improved biomarkers that differentiate patients at low risk of embolic stroke from those in need of CEA to prevent it. This urgent need for improving CEA indication could be met by assessing the structure and composition of carotid plaques. Plaques composed of thin or ruptured fibrous caps (TRFC), large lipid rich necrotic cores (LRNC), and intraplaque hemorrhage (IPH) are associated with thrombosis in morphological studies from autopsy. Further, plaque hemorrhage and increased intraplaque vessel formation in CEA specimens are independently related to future cardio- and cerebrovascular events or interventions. Finally, previous stroke or transient ischemic attack (TIA) is associated with TRFC and IPH - while increased risk of future stroke or TIA is conferred by TRFC, LRNC, and IPH - in human carotid plaques as determined by in vivo magnetic resonance imaging (MRI). The goal of this work is to develop a low-cost, noninvasive imaging method that reliably delineates carotid plaque structure and composition and is suitable for widespread diagnostic application. Previous research has demonstrated that Acoustic Radiation Force Impulse (ARFI) ultrasound delineates LRNC/IPH, collagen/calcium deposits, and TRFC in human carotid plaque, in vivo, with TRFC thickness measurement as low as 0.49 mm - the mean thickness associated with rupture. This project will exploit ARFI Variance of Acceleration (VoA) imaging, higher center frequencies, and harmonic imaging to newly enable separate discrimination of TRFC, LRNC, and IPH and accurate feature size measurement. The investigators will determine the association between advanced ARFI's plaque characterization and recent history of ipsilateral stroke or TIA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: July 16, 2024
• Est. primary completion date: July 16, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. aged 18 years or older

2. having 50-99% stenotic symptomatic carotid plaque with clinical indication for endarterectomy

3. having 50-69% stenotic asymptomatic carotid plaque without clinical indication for endarterectomy

Exclusion Criteria:

1. prior CEA or carotid stenting

2. carotid occlusion

3. vasculitis

4. malignancy

5. inability to provide informed consent

6. prior radiation therapy to the neck

7. treatment with immunomodulating drugs

8. oncological disease.

Related Conditions & MeSH terms

• Carotid Artery Plaque
• Carotid Stenosis
• Plaque, Atherosclerotic

Intervention

Diagnostic Test:
• Acoustic Radiation Force Impulse (ARFI) ultrasound
ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.

Locations

Country	Name	City	State
United States	The University of North Carolina at Chapel Hill Hospitals	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acoustic Radiation Force Impulse (ARFI) imaging	Ability of ARFI imaging to detect carotid plaque features and measure their size	During the procedure
Secondary	VoA AUC for thin or ruptured fibrous caps (TRFC) at 8 MHz fundamental	Area Under the Curve (AUC) for the ability of ARFI Variance of Acceleration (VoA) obtained at 8 MHz fundamental frequency to detect thin or ruptured fibrous cap	During the procedure
Secondary	PD AUC for TRFC at 8 MHz fundamental	AUC for the ability of ARFI PD obtained at 8 MHz fundamental frequency to detect thin or ruptured fibrous cap	During the procedure
Secondary	VoA AUC for TRFC at 12 MHz fundamental	AUC for the ability of ARFI VoA obtained at 12 MHz fundamental frequency to detect thin or ruptured fibrous cap	During the procedure
Secondary	PD AUC for TRFC at 12 MHz fundamental	AUC for the ability of ARFI PD obtained at 12 MHz fundamental frequency to detect thin or ruptured fibrous cap	During the procedure
Secondary	VoA AUC for TRFC at 12 MHz harmonic	AUC for the ability of ARFI VoA obtained at 12 MHz harmonic frequency to detect thin or ruptured fibrous cap	During the procedure
Secondary	PD AUC for TRFC at 12 MHz harmonic	AUC for the ability of ARFI PD obtained at 12 MHz harmonic frequency to detect thin or ruptured fibrous cap	During the procedure
Secondary	VoA AUC for LRNC at 8 MHz fundamental	AUC for the ability of ARFI VoA obtained at 8 MHz fundamental frequency to detect lipid rich necrotic core (LRNC)	During the procedure
Secondary	PD AUC for LRNC at 8 MHz fundamental	AUC for the ability of ARFI PD obtained at 8 MHz fundamental frequency to detect lipid rich necrotic core	During the procedure
Secondary	VoA AUC for LRNC at 12 MHz fundamental	AUC for the ability of ARFI VoA obtained at 12 MHz fundamental frequency to detect lipid rich necrotic core	During the procedure
Secondary	PD AUC for LRNC at 12 MHz fundamental	AUC for the ability of ARFI PD obtained at 12 MHz fundamental frequency to detect lipid rich necrotic core	During the procedure
Secondary	VoA AUC for LRNC at 12 MHz harmonic	AUC for the ability of ARFI VoA obtained at 12 MHz harmonic frequency to detect lipid rich necrotic core	During the procedure
Secondary	PD AUC for LRNC at 12 MHz harmonic	AUC for the ability of ARFI PD obtained at 12 MHz harmonic frequency to detect lipid rich necrotic core	During the procedure
Secondary	VoA AUC for IPH at 8 MHz fundamental	AUC for the ability of ARFI VoA obtained at 8 MHz fundamental frequency to detect intraplaque hemorrhage	During the procedure
Secondary	PD AUC for IPH at 8 MHz fundamental	AUC for the ability of ARFI PD obtained at 8 MHz fundamental frequency to detect intraplaque hemorrhage	During the procedure
Secondary	VoA AUC for IPH at 12 MHz fundamental	AUC for the ability of ARFI VoA obtained at 12 MHz fundamental frequency to detect intraplaque hemorrhage	During the procedure
Secondary	PD AUC for IPH at 12 MHz fundamental	AUC for the ability of ARFI PD obtained at 12 MHz fundamental frequency to detect intraplaque hemorrhage	During the procedure
Secondary	VoA AUC for IPH at 12 MHz harmonic	AUC for the ability of ARFI VoA obtained at 12 MHz harmonic frequency to detect intraplaque hemorrhage	During the procedure
Secondary	PD AUC for IPH at 12 MHz harmonic	AUC for the ability of ARFI PD obtained at 12 MHz harmonic frequency to detect intraplaque hemorrhage	During the procedure
Secondary	VoA bias for TRFC thickness at 8 MHz fundamental	Bland Altman-derived bias in VoA-based TRFC thickness measurement 8 MHz fundamental frequency	During the procedure
Secondary	PD bias for TRFC thickness at 8 MHz fundamental	Bland Altman-derived bias in PD-based TRFC thickness measurement 8 MHz fundamental frequency	During the procedure
Secondary	VoA bias for TRFC thickness at 12 MHz fundamental	Bland Altman-derived bias in VoA-based TRFC thickness measurement at 12 MHz fundamental frequency	During the procedure
Secondary	PD bias for TRFC thickness at 12 MHz fundamental	Bland Altman-derived bias in PD-based TRFC thickness measurement at 12 MHz fundamental frequency	During the procedure
Secondary	VoA bias for TRFC thickness at 12 MHz harmonic	Bland Altman-derived bias in VoA-based TRFC thickness measurement at 12 MHz harmonic frequency	During the procedure
Secondary	PD bias for TRFC thickness at 12 MHz harmonic	Bland Altman-derived bias in PD-based TRFC thickness measurement at 12 MHz harmonic frequency	During the procedure
Secondary	VoA bias for LRNC size at 8 MHz fundamental	Bland Altman-derived bias in VoA-based LRNC size measurement at 8 MHz fundamental frequency	During the procedure
Secondary	PD bias for LRNC size at 8 MHz fundamental	Bland Altman-derived bias in PD-based LRNC size measurement at 8 MHz fundamental frequency	During the procedure
Secondary	VoA bias for LRNC size at 12 MHz fundamental	Bland Altman-derived bias in VoA-based LRNC size measurement at 12 MHz fundamental frequency	During the procedure
Secondary	PD bias for LRNC size at 12 MHz fundamental	Bland Altman-derived bias in PD-based LRNC size measurement at 12 MHz fundamental frequency	During the procedure
Secondary	VoA bias for LRNC size at 12 MHz harmonic	Bland Altman-derived bias in VoA-based LRNC size measurement at 12 MHz harmonic frequency	During the procedure
Secondary	PD bias for LRNC size at 12 MHz harmonic	Bland Altman-derived bias in PD-based LRNC size measurement at 12 MHz harmonic frequency	During the procedure
Secondary	VoA bias for IPH size at 8 MHz fundamental	Bland Altman-derived bias in VoA-based IPH size measurement at 8 MHz fundamental frequency	During the procedure
Secondary	PD bias for IPH size at 8 MHz fundamental	Bland Altman-derived bias in PD-based IPH size measurement at 8 MHz fundamental frequency	During the procedure
Secondary	VoA bias for IPH size at 12 MHz fundamental	Bland Altman-derived bias in VoA-based IPH size measurement at 12 MHz fundamental frequency	During the procedure
Secondary	PD bias for IPH size at 12 MHz fundamental	Bland Altman-derived bias in PD-based IPH size measurement at 12 MHz fundamental frequency	During the procedure
Secondary	VoA bias for IPH size at 12 MHz harmonic	Bland Altman-derived bias in VoA-based IPH size measurement at 12 MHz harmonic frequency	During the procedure
Secondary	PD bias for IPH size at 12 MHz harmonic	Bland Altman-derived bias in PD-based IPH size measurement at 12 MHz harmonic frequency	During the procedure
Secondary	VoA prevalence of TRFC detection at 8 MHz fundamental	prevalence of reader-detected TRFC from VoA at 8 MHz fundamental frequency	During the procedure
Secondary	PD prevalence of TRFC detection at 8 MHz fundamental	prevalence of reader-detected TRFC from PD at 8 MHz fundamental frequency	During the procedure
Secondary	VoA prevalence of TRFC detection at 12 MHz fundamental	prevalence of reader-detected TRFC from VoA at 12 MHz fundamental frequency	During the procedure
Secondary	PD prevalence of TRFC detection at 12 MHz fundamental	prevalence of reader-detected TRFC from PD at 12 MHz fundamental frequency	During the procedure
Secondary	VoA prevalence of TRFC detection at 12 MHz harmonic	prevalence of reader-detected TRFC from VoA at 12 MHz harmonic frequency	During the procedure
Secondary	PD prevalence of TRFC detection at 12 MHz harmonic	prevalence of reader-detected TRFC from PD at 12 MHz harmonic frequency	During the procedure
Secondary	VoA prevalence of LRNC detection at 8 MHz fundamental	prevalence of reader-detected LRNC from VoA at 8 MHz fundamental frequency	During the procedure
Secondary	PD prevalence of LRNC detection at 8 MHz fundamental	prevalence of reader-detected LRNC from PD at 8 MHz fundamental frequency	During the procedure
Secondary	VoA prevalence of LRNC detection at 12 MHz fundamental	prevalence of reader-detected LRNC from VoA at 12 MHz fundamental frequency	During the procedure
Secondary	PD prevalence of LRNC detection at 12 MHz fundamental	prevalence of reader-detected LRNC from PD at 12 MHz fundamental frequency	During the procedure
Secondary	VoA prevalence of LRNC detection at 12 MHz harmonic	prevalence of reader-detected LRNC from VoA at 12 MHz harmonic frequency	During the procedure
Secondary	PD prevalence of LRNC detection at 12 MHz harmonic	prevalence of reader-detected LRNC from PD at 12 MHz harmonic frequency	During the procedure
Secondary	VoA prevalence of IPH detection at 8 MHz fundamental	prevalence of reader-detected IPH from VoA at 8 MHz fundamental frequency	During the procedure
Secondary	PD prevalence of IPH detection at 8 MHz fundamental	prevalence of reader-detected IPH from PD at 8 MHz fundamental frequency	During the procedure
Secondary	VoA prevalence of IPH detection at 12 MHz fundamental	prevalence of reader-detected IPH from VoA at 12 MHz fundamental frequency	During the procedure
Secondary	PD prevalence of IPH detection at 12 MHz fundamental	prevalence of reader-detected IPH from PD at 12 MHz fundamental frequency	During the procedure
Secondary	VoA prevalence of IPH detection at 12 MHz harmonic	prevalence of reader-detected IPH from VoA at 12 MHz harmonic frequency	During the procedure
Secondary	PD prevalence of IPH detection at 12 MHz harmonic	prevalence of reader-detected IPH from PD at 12 MHz harmonic frequency	During the procedure